Literature DB >> 28254856

Considerations for Medication Management and Anticoagulation During Continuous Renal Replacement Therapy.

Ashley Thompson1, Fanny Li1, A Kendall Gross1.   

Abstract

Providing safe and high-quality care to critically ill patients receiving continuous renal replacement therapy (CRRT) includes adequate drug dosing and evaluation of patients' response to medications during therapy. Pharmacokinetic drug studies in acute kidney injury and CRRT are limited, considering the number of medications used in critical care. Therefore, it is important to understand the basic principles of drug clearance during CRRT by evaluating drug properties, CRRT modalities, and how they affect medication clearance. Few published studies have addressed drug disposition and clinical response during CRRT. Additionally, clotting in the CRRT circuit is a concern, so a few options for anticoagulation strategies are presented. This article reviews (1) the CRRT system and drug property factors that affect medication management, (2) the evidence available to guide drug dosing, and (3) anticoagulation strategies for critically ill patients receiving CRRT. ©2017 American Association of Critical-Care Nurses.

Entities:  

Keywords:  CRRT; continuous renal replacement therapy; drug clearance; medication dosing; pharmacokinetics

Mesh:

Year:  2017        PMID: 28254856     DOI: 10.4037/aacnacc2017386

Source DB:  PubMed          Journal:  AACN Adv Crit Care        ISSN: 1559-7768


  2 in total

1.  Monitoring Anticoagulation with Unfractionated Heparin on Renal Replacement Therapy. Which is the Best aPTT Sampling Site?

Authors:  Florin Ioan Anton; Paul Adrian Rus; Natalia Hagau
Journal:  J Crit Care Med (Targu Mures)       Date:  2020-08-11

Review 2.  Antibiotic Dosing in Sustained Low-Efficiency Dialysis in Critically Ill Patients.

Authors:  Sidharth Kumar Sethi; Vinod Krishnappa; Nisha Nangethu; Paul Nemer; Lawrence A Frazee; Rupesh Raina
Journal:  Can J Kidney Health Dis       Date:  2018-08-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.